Advanced search
Publication Cover
Patient Preference and Adherence Volume 14, 2020 - Issue
Submit an article Journal homepage
173
Views
9
CrossRef citations to date
0
Altmetric
Original Research

Oncologist and Patient Preferences for Attributes of CDK4/6 Inhibitor Regimens for the Treatment of Advanced/Metastatic HR Positive/HER2 Negative Breast Cancer: Discrete Choice Experiment and Best–Worst Scaling

Martine C Maculaitis1 Kantar, Health Division, New York, NY, USACorrespondence[email protected]
View further author information
,
Xianchen Liu2 Pfizer Oncology, Pfizer Inc, New York, NY, USAORCID Iconhttps://orcid.org/0000-0002-4325-2545View further author information
ORCID Icon,
Oliver Will3 Kantar, Health Division, Horsham, PA, USAView further author information
,
Madelyn Hanson4 Kantar, Health Division, St. Louis, MO, USAView further author information
,
Lynn McRoy2 Pfizer Oncology, Pfizer Inc, New York, NY, USAView further author information
,
Alexandra Berk1 Kantar, Health Division, New York, NY, USAView further author information
&
Melissa Crastnopol3 Kantar, Health Division, Horsham, PA, USAView further author information
 show all
Pages 2201-2214 | Published online: 05 Nov 2020

Citations (9)

Keep up to date with the latest research on this topic with citation updates for this article.

Subscribe to citation updates

Read on this site (1)

Kathleen Beusterien, Martine C Maculaitis, Bernadette Hallissey, Michael M Gaschler, Mary Lou Smith & Ernest H Law. (2021) Patient, Oncologist, and Payer Preferences for Adjuvant Endocrine Therapy and CDK4/6 Inhibitor Regimens in Early-Stage Breast Cancer: A Discrete Choice Experiment. Patient Preference and Adherence 15, pages 611-623.
Read now

Articles from other publishers (8)

Ernest H Law & Chris Cameron. (2023) Letter in Reply: indirect comparison of quality-of-life scores between patients with advanced breast cancer receiving palbociclib and abemaciclib in combination with fulvestrant. Journal of Comparative Effectiveness Research.
Crossref
Naiba Nabieva & Peter A. Fasching. (2023) CDK4/6 Inhibitors—Overcoming Endocrine Resistance Is the Standard in Patients with Hormone Receptor-Positive Breast Cancer. Cancers 15:6, pages 1763.
Crossref
Hope S. Rugo, Victoria Harmer, Joyce O’Shaughnessy, Komal Jhaveri, Sara M. Tolaney, Fatima Cardoso, Aditya Bardia, Vikalp Kumar Maheshwari, Sandeep Tripathi, Sina Haftchenary, Purnima Pathak & Peter A. Fasching. (2023) Quality of life with ribociclib versus abemaciclib as first-line treatment of HR+/HER2− advanced breast cancer: a matching-adjusted indirect comparison . Therapeutic Advances in Medical Oncology 15, pages 175883592311528.
Crossref
Shan Jiang, Ru Ren, Yuanyuan Gu, Varinder Jeet, Ping Liu & Shunping Li. (2022) Patient Preferences in Targeted Pharmacotherapy for Cancers: A Systematic Review of Discrete Choice Experiments. PharmacoEconomics 41:1, pages 43-57.
Crossref
Carol Mansfield, Willings Botha, Gerard T. Vondeling, Kathleen Klein, Kongming Wang, Jasmeet Singh & Michelle D. Hackshaw. (2022) Patient preferences for features of HER2-targeted treatment of advanced or metastatic breast cancer: a discrete-choice experiment study. Breast Cancer 30:1, pages 23-35.
Crossref
Ernest Law, Roya Gavanji, Sarah Walsh, Anja Haltner, Rebecca McTavish & Chris Cameron. (2022) Palbociclib versus abemaciclib in HR+/HER2- advanced breast cancer: an indirect comparison of patient-reported end points. Journal of Comparative Effectiveness Research 11:2, pages 109-120.
Crossref
Paul Cottu, Scott David Ramsey, Oriol Solà-Morales, Patricia A. Spears & Lockwood Taylor. (2022) The emerging role of real-world data in advanced breast cancer therapy: Recommendations for collaborative decision-making. The Breast 61, pages 118-122.
Crossref
Yue Wang, Zhangyi Wang, Zhao Wang, Xuechun Li, Xiaoli Pang & Shuling Wang. (2021) Application of Discrete Choice Experiment in Health Care: A Bibliometric Analysis. Frontiers in Public Health 9.
Crossref

Related research

People also read lists articles that other readers of this article have read.

Recommended articles lists articles that we recommend and is powered by our AI driven recommendation engine.

Cited by lists all citing articles based on Crossref citations.
Articles with the Crossref icon will open in a new tab.